Clinical studies of docetaxel (Taxotere) and concomitant chest therapy.
Semin Oncol
; 24(4 Suppl 14): S14-26-S14-29, 1997 Aug.
Article
em En
| MEDLINE
| ID: mdl-9335521
ABSTRACT
The administration of concomitant chemoradiotherapy has been shown to increase local and regional control of non-small cell lung cancer. Docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) has single-agent activity in non-small cell lung cancer, as well as radiation-enhancing potential in preclinical studies. Therefore, its investigation with concomitant radiotherapy in the clinical setting is justified. Since the clinical interactions of docetaxel and concomitant chest radiotherapy have not been previously described, we initiated a phase I study with the goal of determining the maximum tolerated dose of docetaxel and the optimal schedule for its administration during a standard course of radiation therapy to the chest, in addition to defining the dose-limiting toxicities of this regimen. This report describes the design and preliminary results of this study.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Paclitaxel
/
Carcinoma Pulmonar de Células não Pequenas
/
Taxoides
/
Neoplasias Pulmonares
/
Antineoplásicos Fitogênicos
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Semin Oncol
Ano de publicação:
1997
Tipo de documento:
Article
País de afiliação:
Estados Unidos